Status:
TERMINATED
Classification and Characterization of Patients Treated With Efalizumab for Plaque Psoriasis
Lead Sponsor:
Norwegian University of Science and Technology
Conditions:
Plaque Psoriasis
Eligibility:
All Genders
18+ years
Brief Summary
The main objectives of the project are: * To classify patients suffering from plaque psoriasis responding on a given treatment (efalizumab) based upon reduction in Psoriasis Area and severity Index (...
Detailed Description
This is an investigator initiated,prospective, longitudinal, observation study. Before starting treatment with efalizumab we will record factors such as demographic data, type of psoriasis, previous t...
Eligibility Criteria
Inclusion
- moderate to severe plaque psoriasis for more than six months
- eligible for efalizumab treatment according to current Norwegian guidelines
Exclusion
- Pregnant or breast-feeding patients
- Patients with a history of uncontrolled bacterial, viral, fungal or atypical mycobacterial infection.
- Patients suffering from HIV, Hepatitis B or C, active tuberculosis, hepatic cirrhosis and hospital admission for cardiac disease, stroke or pulmonary disease within last year.
- Patients with history of cancer in the preceding 5 years, including lymphoproliferative disorders. patients with history of fully resolved basal cell or squamous cell skin cancer may be enrolled.
- Patients with impaired renal or hepatic function.
Key Trial Info
Start Date :
May 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2008
Estimated Enrollment :
96 Patients enrolled
Trial Details
Trial ID
NCT00184366
Start Date
May 1 2005
End Date
July 1 2008
Last Update
January 19 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dep of dermatology, St Olavs Hospital
Trondheim, Norway, 7006